Skip to Content
Merck
  • Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma

Oncotarget (2017-09-15)
Thomas Graillon, David Romano, Céline Defilles, Christophe Lisbonis, Alexandru Saveanu, Dominique Figarella-Branger, Pierre-Hugues Roche, Stéphane Fuentes, Olivier Chinot, Henry Dufour, Anne Barlier
ABSTRACT

Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtype 1 (SST1), SST2, SST3, and SST5 with a high affinity. Pasireotide has a better antisecretory effect in acromegaly, Cushing's disease, and neuroendocrine tumors than octreotide. In this study, we compared the effects of pasireotide to those of octreotide

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human EIF4EBP1
Sigma-Aldrich
Octreotide, ≥98% (HPLC)